Published in final edited form as:

Tetrahedron Lett. 2010 August 18; 51(33): 4411–4414. doi:10.1016/j.tetlet.2010.06.071.

Novel galactosyl donor with 2-naphthylmethyl (NAP) as the non participating group at C-2 position: Efficient synthesis of α -galactosyl ceramide

Sirajud D. Khaja, Vipin Kumar, Misbah Ahmad, Jun Xue, and Khushi L. Matta*

Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

Abstract

Predominant α -linked products can be generated in glycosylation involving galactosyl trichloroacetimidate donors with 2-naphthylmethyl (NAP) as the non participating group at C-2 position. The above donor was successfully utilized for the synthesis of α -galactosyl ceramide.

Keywords

Glycans; α -galactosyl ceramide; 2-naphthylmethyl (NAP); oligosaccharides

1. Introduction

Glycans, the vital endogenous biomolecules, found mostly in conjugation with lipids (to form glycolipids) and proteins (to form glycoproteins), are composed of various monosaccharide units linked together through *O*-glycosidic linkages. They are crucially engaged in various biochemical pathways and biological processes viz., cell-cell communication, cell adhesion, immune response, molecular recognition, tissue repair, microbial and viral pathogenesis.¹ Therefore, practical and stereocontrolled synthesis of glycans occupies great importance in carbohydrate chemistry where a glycosylation reaction involving a donor and acceptor can yield α - as well as β - isomers during the glycosidic bond formation.² Despite the enormous efforts put in by various groups for the development of efficient and stereoselective glycosylation methodologies, not all problems are completely answered.³ In carbohydrate chemistry, generally, it is believed that the glycosylation with glycosyl donors possessing an *O*-acyloxyl group at C-2 usually affords 1,2-*trans* glycoside with quite high stereoselectivity by virtue of its neighboring group participation.^{2k,n,4} But, some reports revealed unusual 1,2-*cis*-glycosylation,⁵ α -(1 $\rightarrow$ 3)-glycosylations⁶ and 1,2-*cis*-galactosylations⁷ with glycosyl donors having a C-2 ester capable of neighboring group participation.

Stereoselective synthesis of 1,2-*cis* glycosides is usually a more difficult issue where no assistance by neighboring group participation is available.^{2f} For instance, the stereoselective construction of certain 1,2-*cis* glycosyl linkages such as α -glucopyranosyl,⁸ α -galactopyranosyl,⁹ α -arabinofuranosyl,¹⁰ α -sialyl linkages¹¹ and β -mannopyranosyl¹² still

Fax: 716-845-8768, khushi.matta@roswellpark.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

presents significant challenge as each case requires a special strategy when applied to construct a complex carbohydrate structure.

In general, a non-assisting functionality at C-2 position of glycosyl donors in most cases is a benzyl, a substituted benzyl or allyl group for the introduction of 1,2-*cis*-glycosidic linkages. Invariably, the use of these glycosyl donors leads to the formation of mixtures of anomers.^{2f} Time-consuming purification protocols are required for the separation of these anomers which also results in the loss of material. In order to find a better stereoselective glycosylation methodology, we became interested in checking the influence of 2-naphthylmethyl (NAP) group as a non participating group in 1,2-*cis* α -galactosyl bond formation as it is endowed with versatile properties such as stability to variety of acidic and basic conditions, selective introduction and chemoselective removal.¹³ With the intention of studying the stereoselectivity-structure relationship, a variety of donors (with *O*-NAP group at C-2) and acceptors were used for coupling together (Table 1). Herein, we describe the results for the above coupling reactions and successful application of our findings to the synthesis of biologically important α -galactosyl ceramide **24**.¹⁴ Synthesis of modified analogs of this molecule is the focus of attention in numerous laboratories.¹⁴

2. Results and Discussion

Galactosyl imidates used for 1,2-*cis* galactosylations suffer from certain drawbacks. For example, 2,3,4,6-tetra-*O*-benzyl-galactosyl donor generates anomeric mixtures which are difficult to purify after glycosylation.^{9c} Furthermore, its 4,6-benzylidene derivative is highly unstable and difficult to isolate and store.^{9c} Inspired by the past success of NAP group in glycosylation, we became interested in exploring the applicability of NAP group being utilized as a non participating group in α -glycosylations.¹⁵

We designed the synthesis of galactosyl donor **4** starting from D-galactose pentaacetate (**1**). Treatment of **1** with ethanethiol and BF₃·OEt₂ at 0 °C gave β -ethylthio galactoside,¹⁶ which on Zemplén deacetylation¹⁷ provided crystalline β -thioethyl galactoside **2** in 92% yield over two steps. Benzylidene protection of β -galactoside **2** with benzaldehyde dimethylacetal and PTSA followed by naphthylmethylation¹³ of 2,3-hydroxyl groups provided the compound **3** as a white solid in 78 % yield (for two steps). Removal of anomeric ethylthio group of **3** was accomplished using NBS,¹⁸ followed by activation of the resultant hemiacetal with trichloroacetonitrile in presence of DBU as base,^{9c} afforded the imidate **4** in 74% yield over two steps (Scheme 1).

We first examined the use of compound **4** as a galactosyl donor using benzyl 2,4-dibenzoyl- α -L-fucoside **6** as an acceptor, the reaction gave a moderate yield of disaccharide **7** with low α -selectivity (Entry 1, Table 1). The ¹H NMR spectra of compound **7** showed a doublet at δ 5.63 for anomeric proton with $J_{1,2} = 3.7$ Hz which confirm the α -stereochemistry in the disaccharide **7**. It was found (also reported for similar imidate in literature) that the imidate **4** is very unstable and difficult to store.^{9c} In order to increase the stability and α -selectivity of the donor **4**, the benzylidene protection was replaced with dibenzoyl ester protection. The dibenzoyl ester protection at C-4 and C-6 makes donor **5** less reactive than donor **4** and hence, provides greater possibility of higher selectivity. Thus, removal of benzylidene ring of **3**, followed by conventional dibenzoylation, deprotection of anomeric ethylthio group and finally treatment with trichloroacetonitrile and DBU afforded the desired galactosyl imidate **5** as a white crystalline solid in 58% yield over four steps (Scheme 1). As prerequisite, the galactosyl donor **5** was found to very stable with a long shelf-life. It was found to be stable below 5 °C for over six months. Donor **5** was coupled initially with α -L-fucoside **6** in presence of TMSOTf to give the disaccharide **8** in 88% yield with complete α -selectivity

(Entry 2, Table 1). The ^1H NMR spectra of compound **8** is indicative of the α -stereochemistry in the glycosylation reaction.

Encouraged by the initial results, we tested for the generality and efficiency of α -selectivity of donor **5** with other acceptors. A series of suitably protected mono- and disaccharide acceptors were glycosylated with donor **5** and the results are summarized in the Table 1 (Entry 2-6). It is evident from Table 1 that the donor **5** is a versatile alternative to donor **4**, furnishing the expected α -glycosides with remarkable stereoselectivities (Entries 2, 3, 5 and 6). Presumably, the higher α -selectivity may be attributed to the low reactivity of donor **5** and non-participating nature of NAP group at C-2 position. Also, the effect of remote participation by 4- and 6-benzoyl group for the enhancement of α -selectivity could not be ruled out in this case. It is worth mentioning here that the similar glycosylation reaction when performed with imidate having benzyl group in place of NAP, gave a mixture of α : β products with very high β -selectivity.¹⁹

Having established the utility of novel galactosyl donor **5**, we initiated the synthesis of α -galactosyl ceramide **24** (KRN7000), using this novel galactosyl donor (Scheme 2). Our synthetic route to galactosyl ceramide **24** started with the amidation reaction of hexacosanoic acid and commercially available phytosphingosine. Several attempts of *N*-acylation of sphingosine **17** with DCC and DIC were unsuccessful. Finally, sphingosine **17** was coupled with hexacosanoic acid using HOBt and EDC in DMF at 100 °C to obtain the ceramide chain **18** in 92% yield. Compound **18** was silylated using TBSOTf and lutidine to yield the known TBS ether **1921** in 82% yield. The spectral data (^1H and ^{13}C NMR) of compound **19** obtained were identical with the literature values.²¹ Chemoselective deprotection of **19**, to obtain free primary hydroxyl group, was carried out using 10% aq-TFA in THF at -10 to 10 °C to provide compound **20** in 88% yield.^{20,21} Glycosylation of **20** with **5** using TMSOTf in THF at -30 °C gave the desired product α -galactosyl ceramide **21** in 68 % yield. The stereoselectivity of the glycosylation was readily determined by ^1H and ^{13}C NMR spectral analysis of compound **21**. Complete deprotection of **21** was carried out in three steps. First, removal of silyl groups of the ceramide chain of **21** was realized using TBAF in THF to furnish **22** in 86% yield. Next, treatment of **22** with NaOMe/MeOH resulted in the deprotection of benzoyl groups on galactose sugar affording **23** in quantitative yield. Finally, hydrogenolysis of NAP groups of **23** yielded the desired KRN7000 **24** in quantitative yield. The spectroscopic data for **24** were in accord with those previously reported in the literature.²¹

3. Conclusions

In summary, the findings described above indicated that the α -linked glycosidic bond can be easily accessed using NAP as a non participating group at C-2 position of the galactosyl donor **5**. As indicated by the results from glycosylation reactions, it appears that increased α -selectivity in case of donor **5** is due to its lower reactivity coupled with the remote participation by 4- and 6-benzoyl group. Moreover, the NAP protecting group is found to be versatile in terms of introduction and removal. Glycosylation with this donor was successfully applied for the synthesis of KRN7000.

Acknowledgments

We acknowledge grant support from DOD (W81XWH-06-1-0013) and support, in part, by the NCI Cancer Center Support Grant to the Roswell Park Cancer Institute (5R21CA121294-02) and core P30 CA 016056.

References and Notes

- (a) Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. *Science*. 2001; 291:2370–2376. [PubMed: 11269318] (b) Gagneau P, Varki A. *Glycobiology*. 1999; 9:747–755. [PubMed: 10406840] (c) Dwek RA. *Chem Rev*. 1996; 96:683–720. [PubMed: 11848770] (d) Varki A. *Glycobiology*. 1993; 3:97–130. [PubMed: 8490246] (e) Hart GW. *Curr Opin Cell Biol*. 1992; 4:1017–1023. [PubMed: 1485955] (f) Paulson JC. *Trends Biochem Sci*. 1989; 14:272–276. [PubMed: 2672447] (g) Rademacher TW, Parekh RB, Dwek RA. *Annu Rev Biochem*. 1988; 5:785–838. [PubMed: 3052290]
- (a) Zhu X, Schmidt RR. *Angew Chem Int Ed Engl*. 2009; 48:1900–1934. [PubMed: 19173361] (b) Demchenko, AV. *Handbook of Chemical Glycosylation*. Wiley-VCH; Weinheim: 2008. (c) Galonic DP, Gin DY. *Nature*. 2007; 446:1000–1007. [PubMed: 17460660] (d) Bongat AFG, Demchenko AV. *Carbohydrate Res*. 2007; 342:374–406. (e) Toshima K. *Carbohydr Res*. 2006; 341:1282–1297. [PubMed: 16630601] (f) Demchenko AV. *Synlett*. 2003:1225–1240. (g) Jensen KJ. *J Chem Soc Perkin Trans 1*. 2002:2219–2233. (h) Bertozzi CR, Kiessling LL. *Science*. 2001; 291:2357–2364. [PubMed: 11269316] (i) Koeller KM, Wong CH. *Chem Rev*. 2000; 100:4465–4493. [PubMed: 11749355] (j) Jung KH, Müller M, Schmidt RR. *Chem Rev*. 2000; 100:4423–4442. [PubMed: 11749353] (k) Boons GJ. *Contemp Org Synth*. 1996; 3:173–200. (l) Boons GJ. *Tetrahedron*. 1996; 52:1095–1121. (m) Schmidt RR, Kinzy W. *Adv Carbohydr Chem Biochem*. 1994; 50:21–123. [PubMed: 7942254] (n) Toshima K, Tatsuta K. *Chem Rev*. 1993; 93:1503–531. (o) Schmidt RR. *Angew Chem Int Ed Engl*. 1986; 25:212–235. (p) Paulsen H. *Angew Chem Int Ed Engl*. 1982; 21:155–173.
- (a) Ernst, B.; Hart, G.; Sinaÿ, P., editors. *Oligosaccharides in Chemistry and Biology: A Comprehensive Handbook Vol I*. Wiley-VCH; Weinheim: 2000. (b) Davis B. *J Chem Soc, Perkin Trans 1*. 2000:2137–2160. (c) Schmidt RR, Jung KH. *Carbohydr Eur*. 1999; 27:12–21. (d) Hanessian, S., editor. *Preparative Carbohydrate Chemistry*. Marcel Dekker Inc.; New York, Basel, Hong Kong: 1997. (e) Khan, SH.; O'Neill, RA., editors. *Modern Methods in Carbohydrate Chemistry*. Harwood Academic Publishers; Amsterdam: 1996.
- (a) Yang G, Kong F. *Synlett*. 2000:1423–1426. (b) Figueroa-Perez S, Verez-Bencomo V. *Tetrahedron Lett*. 1998; 39:9143–9146. (c) Nicolaou KC, Winssinger N, Pastor J, DeRoose F. *J Am Chem Soc*. 1997; 119:449–450. (d) Ogawa T. *Chem Soc Rev*. 1994; 23:397–407. (e) Sinaÿ P. *Pure Appl Chem*. 1991; 63:519–528. (f) Schmidt RR. *Pure Appl Chem*. 1989; 61:1257–1270. (g) Kovac P, Taylor RB, Glaudemans CPJ. *J Org Chem*. 1985; 50:5323–5333. (h) Paulsen H. *Chem Soc Rev*. 1984; 13:15–45.
- Spijker NM, van Boeckel CAA. *Angew Chem, Int Ed Engl*. 1991; 30:180–183.
- Zeng Y, Ning J, Kong F. *Tetrahedron Lett*. 2002; 43:3729–3733.
- Chen L, Kong F. *Tetrahedron Lett*. 2003; 44:3691–3695.
- (a) Crich D, Li L. *J Org Chem*. 2007; 72:1681–1690. [PubMed: 17266375] (b) Crich D, Vinogradova O. *J Org Chem*. 2006; 71:8473–8480. [PubMed: 17064022] (c) Kim JH, Yang H, Boons GJ. *Angew Chem, Int Ed*. 2005; 44:947–949.
- (a) Fan GT, Pan Ys, Lu KC, Cheng YP, Lin WC, Lin S, Lin CH, Wong CH, Fang JM, Lin CC. *Tetrahedron*. 2005; 61:1855–1862. (b) Plettenburg O, Bodmer-Narkevitch V, Wong CH. *J Org Chem*. 2002; 67:4559–4564. [PubMed: 12076157] (c) Figueroa-Pérez S, Schmidt RR. *Carbohydrate Res*. 2000; 328:95–102.
- Zhu X, Kawatkar S, Rao Y, Boons GJ. *J Am Chem Soc*. 2006; 128:11948–11957. [PubMed: 16953636]
- (a) Tanaka H, Nishiura Y, Takahashi T. *J Am Chem Soc*. 2008; 130:17244–17245. [PubMed: 19053458] (b) Halcomb RL, Chappell MD. *J Carbohydr Chem*. 2002; 7-9:723–768.
- (a) Baek JY, Lee BY, Jo MG, Kim KS. *J Am Chem Soc*. 2009; 131:17705–17713. [PubMed: 19908841] (b) Kim KS, Fulse DB, Baek JY, Lee BY, Jeon HB. *J Am Chem Soc*. 2008; 130:8537–8547. [PubMed: 18528988] (c) Crich D, Wu B, Jayalath P. *J Org Chem*. 2007; 72:6806–6815. [PubMed: 17665957] (d) Crich D, Jayalath P. *Org Lett*. 2005; 7:2277–2280. [PubMed: 15901188] (e) Crich D, Jayalath P, Hutton TK. *J Org Chem*. 2006; 71:3064–3070. [PubMed: 16599600]
- (a) Kumar V, Xue J, Locke RD, Matta KL. *Synlett*. 2009:2633–2636. (b) Xia J, Abbas SA, Locke RD, Piskorz CF, Alderfer JL, Matta KL. *Tetrahedron Lett*. 2000; 41:169–173.

14. (a) Xia C, Zhang W, Zhang Y, Woodward RL, Wang J, Wang PG. *Tetrahedron*. 2009; 65:6390–6395. (b) Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M. *Vaccine*. 2008; 26:1807–1816. [PubMed: 18329757] (c) Morales-Serna JA, Boutureira O, Díaz Y, Matheu MI, Castellón S. *Carbohydrate Res*. 2007; 342:1595–1612.
15. (a) Szabó ZB, Borbás A, Bajza I, Liptak A. *Tetrahedron: Asymmetry*. 2005; 16:83–95. (b) Ishiwata A, Ito Y. *Trends Glycosci Glyc*. 2009; 21:266–289.
16. Ellervik U, Magnusson G. *Carbohydrate Res*. 1996; 280:251–260.
17. Zemplén G, Pacsu E. *Ber Dtsch Chem Ges*. 1929; 62:1613–1614.
18. Hanashima S, Akai S, Sato KI. *Tetrahedron Lett*. 2008; 49:5111–5114.
19. Cheng YP, Chen HT, Lin CC. *Tetrahedron Lett*. 2002; 43:7721–7723.
20. Zhou XT, Forestier C, Goff RD, Li C, Teyton L, Bendelac A, Savage PB. *Org Lett*. 2002; 4:1267–1270. [PubMed: 11950339]
21. Takikawa H, Muto S, Mori K. *Tetrahedron*. 1998; 54:3141–3150.
22. The selected analytical data of key compounds are listed: *Compound 5*: ^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.62 (s, 1H), 8.02 (d, J = 8.9 Hz, 2H), 7.98 (d, J = 6.9 Hz, 2H), 7.85–7.72 (m, 5H), 7.71–7.64 (m, 2H), 7.60–7.52 (m, 3H), 7.50–7.32 (m, 10H), 6.67 (d, J = 2.9 Hz, 1H), 6.04 (d, J = 1.9 Hz, 1H), 5.04 (d, J = 11.8 Hz, 1H), 4.96 (dd, J = 12.8 Hz, 17.7 Hz, 2H), 4.83 (d, J = 11.8 Hz, 1H), 4.59 (t, J = 5.9 Hz, 1H), 4.52–4.45 (m, 1H), 4.37 (dd, J = 5.9 Hz, 11.8 Hz, 1H), 4.25 (dt, J = 2.9 Hz, 9.8 Hz, 12.7 Hz, 2H). *Compound 8*: ^1H NMR (400 MHz, CDCl_3): δ (ppm) = 7.99–8.12 (m, 6H), 7.88 (d, J = 8.1 Hz, 2H), 7.69 (dd, J = 8.1 Hz, 15.4 Hz, 2H), 7.28–7.62 (m, 20H), 7.14–7.26 (m, 9H), 5.93 (s, 1H), 5.58 (d, J = 3.7 Hz, 10.3 Hz, 1H, H-1), 5.47 (d, J = 2.93 Hz, 1H, H-1'), 5.54 (d, J = 2.9 Hz, 1H), 5.31 (d, J = 3.7 Hz, 1H), 4.87 (dd, J = 4.4 Hz, 7.3 Hz, 1H), 4.74–4.81 (m, 1H), 4.61–4.71 (m, 2H), 4.51–4.60 (m, 2H), 4.42–4.50 (m, 2H), 4.36 (d, J = 11.7 Hz, 1H), 4.30 (d, J = 11.7 Hz, 1H), 3.98 (dd, J = 6.6 Hz, 13.2 Hz, 1H), 3.87–3.95 (m, 2H), 1.10 (d, J = 5.9 Hz, 3H). *Compound 10*: ^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.04 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 7.3 Hz, 2H), 7.81–7.66 (m, 6H), 7.61–7.51 (m, 4H), 7.49–7.38 (m, 8H), 7.30 (t, J = 8.1 Hz, 2H), 5.83–5.72 (m, 2H), 5.79 (d, J = 2.9 Hz, 1H), 5.52 (d, J = 2.9 Hz, 1H), 5.28 (d, J = 2.9 Hz, 1H), 5.25–5.21 (m, 1H), 5.20–5.18 (m, 1H), 5.17–5.12 (m, 1H), 4.95 (d, J = 10.9 Hz, 1H), 4.83 (d, J = 4.4 Hz, 1H), 4.80 (d, J = 10.9 Hz, 1H), 4.47 (dd, J = 4.4 Hz, 10.9 Hz, 1H), 4.38–4.26 (m, 2H), 4.10 (d, J = 6.6 Hz, 2H), 4.03 (dd, J = 3.6 Hz, 8.1 Hz, 2H), 3.97 (d, J = 8.1 Hz, 1H), 3.93–3.83 (m, 3H), 3.57 (t, J = 6.6 Hz, 1H), 2.08 (s, 3H), 1.86 (s, 3H), 1.84 (s, 3H). *Compound 14*: ^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.13–8.00 (m, 6H), 7.88 (d, J = 8.1 Hz, 2H), 7.70 (t, J = 8.8 Hz, 2H), 7.60–7.51 (m, 4H), 7.50–7.27 (m, 16H), 7.26–7.15 (m, 4H), 6.73 (d, J = 8.1 Hz, 1H), 5.94 (d, J = 1.4 Hz, 1H), 5.83–5.72 (m, 1H), 5.60 (dd, J = 3.7 Hz, 10.3 Hz, 1H), 5.55 (d, J = 2.9 Hz, 1H), 5.47 (d, J = 2.9 Hz, 1H), 5.29 (d, J = 3.6 Hz, 1H), 5.27–5.09 (m, 2H), 4.92–4.86 (dd, J = 4.4 Hz, 8.1 Hz, 1H), 4.78 (d, J = 11.7 Hz, 1H), 4.67 (dd, J = 2.9 Hz, 10.3 Hz, 1H), 4.62–4.55 (m, 1H), 4.49–4.42 (m, 2H), 4.32 (dd, J = 12.4 Hz, 24.8 Hz, 2H), 4.15–4.08 (m, 1H), 3.97 (dd, J = 5.8 Hz, 13.2 Hz, 2H), 3.92 (dd, J = 2.2 Hz, 7.3 Hz, 2H), 1.12 (d, J = 6.6 Hz, 3H). *Compound 21*: ^1H NMR δ (ppm) = 8.04–7.98 (m, 4H), 7.68–7.83 (m, 7H), 7.65 (d, J = 7.96, 1H), 7.62 (d, J = 7.96, 1H), 7.52–7.58 (m, 2H), 7.33–7.51 (m, 9H), 5.98 (d, J = 2.7 Hz, 1H), 5.92 (d, J = 7.92 Hz, 1H), 5.04 (d, J = 11.5 Hz, 1H), 5.00 (d, J = 3.1 Hz, 1H), 4.96 (d, J = 11.9 Hz, 1H), 4.87 (d, J = 11.9 Hz, 1H), 4.76 (d, J = 11.5 Hz, 1H), 4.47 (dd, J = 5.8 Hz, 11.1 Hz, 1H), 4.39 (t, J = 6.6 Hz, 1H), 4.29 (dd, J = 7.1 Hz, 11.1 Hz, 1H), 4.20–4.26 (m, 1H), 4.17 (dd, J = 3.1 Hz, 9.7 Hz, 1H), 4.10–4.15 (m, 1H), 4.05 (dd, J = 3.5 Hz, 10.2 Hz, 1H), 3.91–3.95 (m, 1H), 3.76 (t, J = 8.8 Hz, 1H), 3.67 (m, 1H), 1.91–1.96 (m, 2H), 1.44–1.51 (m, 6H), 1.18–1.33 (m, 66H), 0.88–0.90 (m, 6H), 0.91 (s, 9H), 0.87 (s, 9H), 0.07 (s, 3H), 0.04 (s, 6H), 0.03 (s, 3H); ^{13}C NMR (400 MHz, CDCl_3): δ (ppm) = 173.1, 135.6, 135.6, 133.3, 133.2, 133.1, 133.1, 133.0, 132.9, 129.9, 129.8, 129.7, 129.7, 128.4, 128.3, 128.2, 127.2, 127.7, 127.6, 127.0, 126.4, 126.1, 126.0, 125.9, 125.8, 125.7, 99.8, 76.6, 76.0, 75.6, 75.1, 73.8, 72.0, 68.6, 68.4, 67.4, 62.5, 51.6, 36.8, 33.6, 31.9, 29.9, 29.7, 29.68, 29.64, 29.60, 29.5, 29.43, 29.38, 29.33, 26.1, 26.0, 25.6, 22.6, 18.5, 18.3, 18.1, 14.1, -3.7, -3.9, -4.6, -4.8. *Compound 22*: ^1H NMR δ (ppm) = 8.04–7.95 (t, J = 8.7 Hz, 4H), 7.85–7.72 (m, 5H), 7.62–7.72 (m, 3H), 7.52–7.60 (m, 2H), 7.35–7.51 (m, 10H), 6.22 (d, J = 8.8 Hz, 1H), 5.95 (d, J = 2.9 Hz, 1H), 5.04 (m, 3H), 4.87 (d, J = 11.7 Hz, 1H), 4.77 (d, J = 10.9 Hz, 1H), 4.43–4.49 (m, 1H), 4.42–4.35 (m, 3H), 4.12–4.17 (m, 1H), 4.04 (dd, J = 3.7 Hz, 9.5 Hz, 1H), 3.98 (dd, J = 3.7 Hz, 10.3 Hz, 1H), 3.89 (dd, J = 2.9 Hz, 10.2 Hz, 1H), 3.45–3.56 (m, 2H), 2.27 (bs, H) 2.08 (t, J = 8.1 Hz, 2H), 1.53–1.62 (m, 6H), 1.06–1.37 (m, 66H), 0.88 (t, J = 7.3 Hz, 6H); ^{13}C NMR δ (ppm) = 172.9, 171.9, 133.6, 133.5,

130.2, 130.0, 128.8, 128.7, 128.4, 128.3, 128.2, 128.0, 127.9, 127.6, 126.9, 126.5, 126.4, 126.3, 126.2, 126.1, 99.2, 77.7, 77.3, 76.7, 76.1, 74.9, 74.6, 73.5, 72.2, 69.9, 68.4, 67.8, 63.3, 49.7, 37.0, 33.7, 32.2, 30.0, 29.8, 29.7, 29.7, 29.6, 26.5, 26.0, 22.9, 14.4. *Compound 23*: ^1H NMR δ (ppm) = 7.72-7.87 (m, 8H), 7.53-7.43 (m, 6H), 6.46 (d, J = 8.1 Hz, 1H), 4.99 (d, J = 3.7 Hz, 1H), 4.98 (d, J = 3.6 Hz, 1H), 4.90 (s, 2H), 4.86 (d, J = 11.7 Hz, 1H), 4.27 (d, J = 3.6 Hz, 1H), 4.11 (s, 1H), 3.91-4.00 (m, 3H), 3.81-3.91 (m, 3H), 3.70-3.78 (m, 2H), 3.48 (s, 2H), 2.08 (t, J = 7.3 Hz), 1.47-1.66 (m, 6H), 1.37-1.46 (m, H), 1.05-1.38 (m, 66H), 0.89 (t, J = 6.6 Hz, 6H); ^{13}C NMR δ (ppm) = 173.3, 134.94, 134.91, 133.0, 132.9, 128.23, 128.20, 127.8, 127.7, 127.55, 127.52, 126.7, 126.5, 126.1, 126.0, 125.99, 125.93, 125.6, 125.5, 98.4, 77.6, 76.1, 75.4, 74.0, 73.0, 72.4, 70.0, 68.9, 68.4, 62.7, 49.8, 36.8, 33.6, 32.0, 29.8, 29.7, 29.5, 29.4, 29.3, 25.9, 25.84, 22.80, 14.3.

Scheme 1.

Preparation of donor **4** and **5**. *Reagents and conditions:* (a) (i) DCM-Ethanethiol (2.5 eq)-BF₃·Et₂O (1.5eq), 0 °C, 6 h; (ii) NaOMe (1 M), MeOH, r.t., 20 h, 92% for 2 steps; (b) (i) PhCH(OMe)₂ (2 eq), *p*-TsOH (0.1 eq), r.t., 6 h; (ii) NAP-Br (2.8 eq), NaH (4 eq), THF, r.t., 6 h, 78% for 2 steps; (c) (i) NBS (1.4 eq), acetone, 0 °C, 2 h; (ii) CCl₃CN (10 eq), DBU (0.5 eq), CH₂Cl₂, 0 °C, 30 min., 74% for 2 steps; (d) (i) 60% HOAc, 60 °C, 5 h; (ii) BzCl (3 eq), py, r.t., 6 h, (iii) NBS (1.4 eq), acetone, 0 °C, 2 h; (iv) CCl₃CN (10 eq), DBU (0.5 eq), CH₂Cl₂, 0 °C, 30 min. 58%.

Scheme 2.

Synthesis of α -galactosyl ceramide **24**. (a) hexacosanoic acid (1 eq), EDC (2 eq), HOBT (1.1 eq), DMF, 100 °C, 6 h, 92%; (b) TBSOTf (5 eq), 2,6-lutidine (15 eq), CH₂Cl₂, 82%; (c) 10% aq. TFA, -10 to 10 °C, 2 h, 88%; (d) **5** (1.2 eq), TMSOTf (0.3 eq), anhydrous THF, -30 °C, 4 h, 68%; (e) TBAF (4 eq), THF, 3 h, 86%; (f) NaOMe (1 M), CH₃OH, rt, 6 h, 100%. (g) H₂, Pd-C (10 %), CH₃OH, 8 h, 100%.

Table 1

^a Coupling results with different donors and acceptors.

Entry	Donor (1.2 eq)	Acceptor (1 eq)	Product	Yield (%)	Ratio (α/β)
1.	4			68	9:1
2.	5	6		88	Only α
3.	5			82	Only α
4.	5			68	6.2:1
5.	5			78	Only α

Entry	Donor (1.2 eq)	Acceptor (1 eq)	Product	Yield (%)	Ratio (α/β)
6.	5	15	16	74	Only α

^a All the reactions were conducted using TMSOTf (0.2 eq.) in CH₂Cl₂ and at -15 °C. The reactions were completed within 3-4 hrs.